Lawrence Mayer, PhD,

Dr. Lawrence Mayer on CPX-351 for Acute Myeloid Leukemia

January 23rd 2015

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).